American Bio Medica (American Bio Medica) LT-Debt-to-Total-Asset : 0.00 (As of Mar. 2023)

View and export this data going back to . Start your Free Trial

What is American Bio Medica LT-Debt-to-Total-Asset?

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. American Bio Medica's long-term debt to total assests ratio for the quarter that ended in Mar. 2023 was 0.00.

American Bio Medica's long-term debt to total assets ratio declined from Mar. 2022 (0.00) to Mar. 2023 (0.00). It may suggest that American Bio Medica is progressively becoming less dependent on debt to grow their business.

American Bio Medica LT-Debt-to-Total-Asset Historical Data

The historical data trend for American Bio Medica's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

American Bio Medica LT-Debt-to-Total-Asset Chart

American Bio Medica Annual Data

Trend

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

LT-Debt-to-Total-Asset

Get a 7-Day Free Trial

0.32

0.57

0.60

0.01

American Bio Medica Quarterly Data
	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23
LT-Debt-to-Total-Asset	Get a 7-Day Free Trial															-	-	0.01	0.01	-

American Bio Medica LT-Debt-to-Total-Asset Calculation

American Bio Medica's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Dec. 2022 is calculated as

LT Debt to Total Assets (A: Dec. 2022 )	=	Long-Term Debt & Capital Lease Obligation (A: Dec. 2022 )	/	Total Assets (A: Dec. 2022 )
	=	0.006	/	1.269
	=	0.00

American Bio Medica's Long-Term Debt to Total Asset Ratio for the quarter that ended in Mar. 2023 is calculated as

LT Debt to Total Assets (Q: Mar. 2023 )	=	Long-Term Debt & Capital Lease Obligation (Q: Mar. 2023 )	/	Total Assets (Q: Mar. 2023 )
	=	0	/	0.659
	=	0.00

American Bio Medica (OTCPK:ABMC) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

American Bio Medica LT-Debt-to-Total-Asset Related Terms

Thank you for viewing the detailed overview of American Bio Medica's LT-Debt-to-Total-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

American Bio Medica (American Bio Medica) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » American Bio Medica Corp (OTCPK:ABMC) » Definitions » LT-Debt-to-Total-Asset

Comparable Companies

Traded in Other Exchanges

N/A

Address

122 Smith Road, Kinderhook, New York, NY, USA, 12106

Website

https://www.abmc.com

American Bio Medica Corp is a us-based company engaged in manufacturing and selling lateral flow immunoassay tests, primarily for the immediate detection of certain drugs in urine and oral fluids at the point of collection. It also manufactures and sells drug testing products and provides bulk test strip manufacturing services to unaffiliated third parties on a contract basis. The company offers few urine tests which include Rapid Drug Screen, RDS InCup, Rapid TOX, and Rapid TOX Cup II. Its target customer includes workplace, government, corrections, clinical and educational markets. Geographically, it derives a majority of revenue from the United States.

Executives

Stuart Steinberg	10 percent owner	85 BELLEVUE AVENUE, RYE NY 10580
John J Moroney	10 percent owner	118 PEGASUS DR., JUPITER FL 33477
Chaim Davis	director	2601 PINE TREE DRIVE, MIAMI BEACH FL 33140
Peter Jerome	director	7 RIDGECREST AVE, LATHAM NY 12110
Diane Generous	director	122 SMITH ROAD, KINDERHOOK NY 12106
Melissa A Waterhouse	officer: EVP, CCO, CORP SEC	AMERICAN BIO MEDICA CORPORATION, 122 SMITH ROAD, KINDERHOOK NY 12106
Mp Biomedicals Llc	10 percent owner	3 HUTTON CENTRE DRIVE, SUITE 100, SANTA ANA CA 92707
Douglas Casterlin	officer: Executive Vice President	C/O MELISSA A. WATERHOUSE/ABMC, 122 SMITH ROAD, KINDERHOOK NY 12106
Jean Neff	director	C/O ABMC, 122 SMITH ROAD, KINDERHOOK NY 12106
Stefan Parker	officer: Chief Financial Officer	122 SMITH ROAD, KINDERHOOK NY 12106
Carl A Florio	director	C/O HUDSON RIVER BANK & TRUST CO, PO BOX 76, HUDSON NY 12534
Stan Cipkowski	director	300 S LAKE DR, STE 340, FISHKILL NY 12553
Anthony G Costantino	director	122 SMITH ROAD, KINDERHOOK NY 12106
Edmund M Jaskiewicz	director, officer: President
Richard Koskey	director	C/O ABMC 122 SMITH ROAD, 122 SMITH ROAD, KINDERHOOK NY 12106